Vanguard Global Advisers
CGON icon

Vanguard Global Advisers’s CG Oncology CGON Stock Holding History

Vanguard Global Advisers’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.35M Buy
33,034
+2,778
+9% +$182K ﹤0.01% 1152
2026
Q1 		$2.05M Buy
+30,256
New +$1.71M ﹤0.01% 1180

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Global Advisers's CGON Position: Q2 2026 in Review

Vanguard Global Advisers increased its CG Oncology (CGON) stake by 9.2% in Q2 2026, buying an estimated $182K and bringing the position to 33,034 shares worth $2.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1152.

Vanguard Global Advisers first reported a position in CGON in Q1 2026 and has held it in 2 quarters since. 226 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Vanguard Global Advisers held 33,034 shares of CG Oncology worth $2.35M as of Q2 2026.
  • Vanguard Global Advisers bought 2,778 CG Oncology shares in Q2 2026, an estimated $182K.
  • CG Oncology made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1152 holding.
  • Vanguard Global Advisers first reported a position in CG Oncology in Q1 2026 and has held it in 2 quarters since.
  • 226 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.